• Regarding the Omicron vaccine roundup, the CEO of Pfizer, Albert Bourla, told Bloomberg in a worst case existing BioNTech vaccine will retain some effectiveness against Omicron. According to Bourla, the company will be able to provide a definite answer in two to three weeks’ time on the current MRNA vaccine effectiveness, which is about the same timeline as the WHO update on the latest variant that is popping up in more and more countries globally. Furthermore, the Pfizer CEO also said his company needs about 100 days for authorization for a re-formulated vaccine before rolling it out on a large scale.

For the full report, click here